Harvard Bioscience (HBIO) Non Operating Income (2010 - 2026)

Harvard Bioscience (HBIO) has 17 years of Non Operating Income data on file, last reported at -$2.1 million in Q1 2026.

• On a quarterly basis, Non Operating Income fell 89.43% year-over-year to -$2.1 million in Q1 2026; TTM through Mar 2026 was -$11.1 million, a 184.85% decrease from a year earlier, with the FY2025 full-year figure at -$8.8 million, down 61.46% from the prior year.
• Non Operating Income for Q1 2026 stood at -$2.1 million, up from -$6.2 million in the prior quarter.
• Over the last five years, Non Operating Income for HBIO reached as high as $579000.0 in Q4 2024 and fell as low as -$6.2 million in Q4 2025.
• Historically, Non Operating Income has averaged -$1.3 million across 5 years, with a median of -$928000.0 in 2022.
• Across the five-year window, Non Operating Income jumped 141.81% in 2024 and slumped 1178.93% in 2025, its largest moves.
• Year by year, Non Operating Income stood at -$598000.0 in 2022, then slumped by 131.61% to -$1.4 million in 2023, then surged by 141.81% to $579000.0 in 2024, then slumped by 1178.93% to -$6.2 million in 2025, then jumped by 65.86% to -$2.1 million in 2026.
• Per Business Quant data, the three most recent Non Operating Income figures were -$2.1 million in Q1 2026, -$6.2 million in Q4 2025, and -$1.3 million in Q3 2025.